Top 25 Biosimilar Drug Manufacturers 2013-2023

Producers of biosimilars - how to assess products, developments, and revenue prospects
What does the future hold for makers of biosimilar drugs? Visiongain's updated report shows you those companies' prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 25 leading developers, producers and marketers of biosimilars, also with discussion of other companies. There you find information on established and rising organisations. Discover their sales potentials.

That investigation is for everyone interested in the future of biopharmaceuticals. See now how you can benefit.

Forecasts and other data to help you stay ahead in knowledge of those biological drugs
In that report you find analytical profiles of top companies worldwide. There you analyse historical data, R&D, market shares, revenue forecasts, and growth rates. See qualitative analysis too for those biologics. You also gain 97 charts, 44 tables and an interview.
That work lets you assess the most lucrative parts of the industry for biosimilar drugs. Get revenue forecasts to 2023 for eight of the companies. See there how you can benefit your research, analyses, and decisions, also saving time.

Find where money lies for those protein-based medicines. The following sections explain what you get in that new analysis.

Companies based in regions with developed pharma industries

First, our study gives you discussions, financial analyses, and commercial outlooks for six biosimilar drug producers among the leading drug-producing countries:

• Sandoz
• Teva
• Hospira
• Stada Arzneimittel
• Medice Arzneimittel Pütter
• JCR Pharmaceuticals.

You see possibilities there for business performance. Discover what the future holds for those companies, including revenue predictions to 2023 for top firms. Hear too about other companies, including Actavis, Mylan, Pfizer, Boehringer Ingelheim, Mochida, and Nichi-Iko.

China - outlooks for leading biosimilar drug manufacturers

Next, our report analyses five Chinese biosimilar specialists:

• 3SBio
• Beijing SL Pharmaceutical
• GeneScience Pharmaceuticals
• Shanghai Fosun
• Tonghua Dongbao.

Many opportunities remain, with high, expanding revenues possible from 2013. See where best potentials exist.

India - prospects for leading players

You also discover outlooks for six Indian biosimilar specialists:

• Biocon
• Dr. Reddy's Laboratories
• Intas Biopharmaceuticals
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila.

You also hear about activities of Ranbaxy, Cipla, and Lupin. Our report shows you how companies seize opportunities and expand their revenues.

Latin America - analysis of leading biological drug firms

Our new work also assesses four Latin American biosimilar drug producers:

• Probiomed
• Biosidus
• Amega Biotech
• Aché.

You find revenue data, trends, and opportunities there, seeing activities, product ranges, and prospects.

Producers from Central and Eastern Europe (CEE), Russian Federation, and South Korea
You also discover outlooks and activities of companies based in other developing countries:

• Bioton
• Pharmstandard
• LG Life Sciences
• Dong-A Pharmaceutical.

Developing and developed national markets will prove important for biosimilar drug sales from 2013 to 2023, our analyses show. Discover what the future holds.

Revenue prediction for the overall biosimilars market and its submarkets

Our report also forecasts revenues to 2023 for the world biosimilars industry and seven main segments:

• EPO
• Insulin
• Filgrastim
• Somatropin
• Interferons
• FSH
• Monoclonal antibodies (mAbs).

There you see overall world revenues in 2017 reaching $8.8bn. Our analyses reveal high sales growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper.
Ways Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023 helps you
In particular, our new report gives you the following knowledge:

• Profiles of 25 leading companies - assess product ranges, strategies, and sales results, also gaining revenue forecasts to 2023 for 8 organisations
• Competition and opportunities - explore what affects the biosimilars market, finding what shapes its future, esp. prospects for sustaining and developing business
• Revenues to 2023 for that industry at world level, with forecasting of 7 submarkets - discover overall outlooks for commercial success.

Analysis found nowhere else - discover the future of those biologics

Our work gives independent analysis. There you receive competitive intelligence found only in our report. You discover where prospects are most rewarding.

With that investigation you're less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Also find how you could save time and get recognition for understanding, increasing your influence.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

Additional Information
3.4.4.2 Stada: Biosimilar Revenue Forecast, 2013-2023

Between 2012 and 2017, Stada’s biosimilar revenue will grow with a CAGR of 17.1%, growing

from $48m to $106m, visiongain forecasts. This growth will be dependent on the increased uptake

of Silapo in markets such as Germany. Growth will be restrained by increased competition in this

marketplace, driving down prices, as well as decreased demand for EPO products. Beyond the

middle of the forecast period, growth for Stada’s biosimilar revenue will depend upon the launch of

new biosimilar products, in particular its two monoclonal antibodies, which are due to be launched

in 2017. Its biosimilar rituximab is unlikely to be the first launched in the EU, however, and will

therefore compete with other products upon launch. By 2023, Stada’s biosimilar revenue will have

grown to $361m (Table 3.15 and Figure 3.9). During the forecast period, Stada’s biosimilars

market share will fall by almost half, from 2.4% to 1.3% (Figure 3.10).

Companies Listed

3SBio (Shenyang Sunshine Pharmaceutical)
Abbott Laboratories
Aché
Actavis
Affitech
Amega Biotech
Amgen
Amicus Therapeutics
Anglo Gulf (part of MJ Group)
Apotex
Aprogen
ASKA Pharmaceutical
AstraZeneca
Avesthagen
AxiCorp
AzkoNobel
Baxter International
Bayer
Beijing Four Rings Bio-pharmaceutical
Beijing SL Pharmaceutical
Bigpearl Trading (part of Pharmstandard)
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biogen Idec
BioGeneriX (part of Teva)
BioMab
Biomed (part of Pharmstandard)
Bionovis
Biopartners (part of Bioton)
Biopharmaceuticals and Herbal Medicines Bureau [South Korea]
Biosidus (part of Sidus Pharmaceutical Group)
Bioton
Biovel Life Sciences (part of Ranbaxy)
Blau Farmacêutica
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Pharm (part of Stada)
Celltrion
Central Drugs Standard Control Organization (CDSCO) [India]
Chemo Group
China National Pharmaceutical Group (Sinopharm)
CinnaGen
Cipla
CJ Corporation
Clinigene International (part of Biocon)
CoGenesys (part of Teva)
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Committee for Medicinal Products for Human Use (CHMP) [EU]
CT Arzneimittel (part of Teva)
CureTech (part of Teva)
Daiichi Sankyo
Dainippon Sumitomo Pharma
DaVita
Department of Biotechnology (DBT) [India]
Diapin Therapeutics
DM Bio
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Eden Biodesign (part of Watson)
Egis Pharmaceuticals
Eli Lilly
Emcure Pharmaceuticals
EMS
Epitomics
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Finox
Food and Drug Administration (FDA), [US]
Fosun International
Fresenius Medical Care
Fuji Pharma
Fujifilm
Funda??o Ezequiel Dias (Funed) [Brazil]
Gan & Lee Pharmaceutical
Gedeon Richter
Genentech (part of Roche)
GeneScience Pharmaceuticals
Gennova Biopharmaceuticals (part of Emcure Pharmaceuticals)
Genzyme (part of Sanofi)
German Remedies (part of Zydus Cadila)
Germonta Holdings (part of Bioton)
Green Cross Corporation
GSK
Hangzhou Jiuyuan Gene Engineering
Hanwha Chemical
Haselmeier
Hefei-SciGen-Bioton Biopharmaceutical Company
Hemofarm (part of Stada)
Hexal (part of Novartis)
Hikma Pharmaceuticals
Hospira
Hospira Japan (part of Hospira)
Hualida Biotech
Human Genome Sciences (part of GSK)
Hypermarcas
IATRICa
iBio
Insmed
Intas Biopharmaceuticals (part of Intas Pharmaceuticals)
Intas Pharmaceuticals
International Biotech Center (IBC) Generium
Isotechnika Pharma
Isu Abxis
Itero Biopharmaceuticals
JCR Pharmaceuticals
Johnson & Johnson (J&J)
Kissei Pharmaceutical
Korea Food and Drug Administration (KFDA)
Kwizda Pharma
Kyowa Hakko Kirin
Laboratórios Biosintética (part of Aché)
Landsteiner Scientific
Lekko (part of Pharmstandard)
LG
LG Chem Investment (part of LG)
LG Life Sciences
Lonza
Lupin Pharmaceuticals
MabPharm
Marvel Life Sciences (part of MJ Group)
Masterlek (part of Pharmstandard)
Medice Arzneimittel Pütter
MedImmune (part of AstraZeneca)
Meiji Seika Pharma
Merck BioVentures
Merck & Co.
Merck KGaA
Mindar Holdings (part of Bioton)
Ministry of Health [Brazil]
Ministry of Health and Family Welfare [India]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Ministry of Science and Technology [India]
MJ Biopharm (part of MJ Group)
MJ Bioton Life Sciences
MJ Group
Mochida Pharmaceutical
Mylan
NeuClone
Nichi-Iko Pharmaceutical
Nippon Kayaku
Nipro Pharma
Nobel Ilac
Norbitec
Nordmark Arzneimittel
Novartis
Novo Nordisk
Organon (part of Merck & Co.)
Owen Mumford
Parexel International
Pfenex
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Pharmapark (part of Pharmstandard)
Pharmstandard
Pharmstandard-Biolek (part of Pharmstandard)
PlantForm
Pliva (part of Teva)
Polpharma
Polpharma Biologics (part of Polpharma)
Probiomed
Prolong Pharmaceuticals
Proquifin
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
ratiopharm (part of Teva)
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Group
Reliance Life Sciences (part of Reliance Group)
Rentschler Biotechnologie
Roche
Royal DSM
Safety Syringes
Samsung
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
sanofi-aventis Nichi-Iko
Savient Pharmaceuticals (part of Ferring)
Schering-Plough (part of Merck & Co.)
Schnell Biopharmaceuticals
SciGen
Shandong Kexing Bioproducts
Shanghai Celgen Bio-Pharmaceutical
Shanghai Chemo Wanbang Biopharma
Shanghai CP Goujian Pharmaceutical
Shanghai Fosun Pharmaceutical
Shanghai Henlius Biotech
Shantha Biotechnics (part of Sanofi)
Sicor Biotech (part of Teva)
Sidus Pharmaceutical Group
Silanes
Stada Arzneimittel
State Food and Drug Administration (SFDA) [China]
State's Employees′ Social Security and Social Services Institute (ISSSTE) [Mexico]
Sundiro Pharma
Syngene (part of Biocon)
Teva Pharmaceutical Industries
Teva-Kowa Pharma (part of Teva)
The United Laboratories
Therapeutic Goods Administration (TGA) [Australia]
TL Biopharmaceutical
Tonghua Dongbao
Uni?o Química
University of Michigan
Wanbang Biopharmaceuticals (part of Shanghai Fosun Pharmaceuticals)
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Xiamen Amoytop Biotech
Ypsomed
Zao Indar
Zenotech Laboratories
Zuventus Healthcare (part of Emcure Pharmaceuticals)
Zydus Cadila